In this paper, we used two clinically utilized small molecule inhibitors, PPP and ASP3026, to antagonize the oncogenic kinases IGF-IR and ALK, respectively, in NPM-ALK+ T cell lymphoma [24]. The gene discussed is ALK; the disease is T-cell non-Hodgkin lymphoma.